vs
Side-by-side financial comparison of AMES NATIONAL CORP (ATLO) and ClearPoint Neuro, Inc. (CLPT). Click either name above to swap in a different company.
AMES NATIONAL CORP is the larger business by last-quarter revenue ($18.7M vs $10.4M, roughly 1.8× ClearPoint Neuro, Inc.). On growth, ClearPoint Neuro, Inc. posted the faster year-over-year revenue change (34.0% vs 26.7%). AMES NATIONAL CORP produced more free cash flow last quarter ($20.7M vs $-12.1M). Over the past eight quarters, AMES NATIONAL CORP's revenue compounded faster (19.5% CAGR vs 16.7%).
Ames National Corp is a U.S. financial holding company based in Iowa. It operates multiple community banking subsidiaries, offering retail and commercial financial services including deposit accounts, personal and business loans, mortgages, and wealth management, primarily serving consumers and SMEs across central Iowa.
ClearPoint Neuro, Inc. is a medical technology firm specializing in precision neurology solutions. It develops and commercializes intraoperative navigation, targeting and delivery systems for minimally invasive brain surgeries, neurological disorder treatments, and CNS therapy development for global clinical and biopharmaceutical partners.
ATLO vs CLPT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $10.4M |
| Net Profit | $6.5M | — |
| Gross Margin | — | 61.5% |
| Operating Margin | 44.3% | -67.7% |
| Net Margin | 34.9% | — |
| Revenue YoY | 26.7% | 34.0% |
| Net Profit YoY | 85.4% | — |
| EPS (diluted) | — | $-0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.7M | $10.4M | ||
| Q3 25 | $16.6M | $8.9M | ||
| Q2 25 | $16.1M | $9.2M | ||
| Q1 25 | $15.5M | $8.5M | ||
| Q4 24 | $14.7M | $7.8M | ||
| Q3 24 | $13.5M | $8.1M | ||
| Q2 24 | $13.5M | $7.9M | ||
| Q1 24 | $13.1M | $7.6M |
| Q4 25 | $6.5M | — | ||
| Q3 25 | $4.6M | $-5.9M | ||
| Q2 25 | $4.5M | $-5.8M | ||
| Q1 25 | $3.4M | $-6.0M | ||
| Q4 24 | $3.5M | — | ||
| Q3 24 | $2.2M | $-5.0M | ||
| Q2 24 | $2.2M | $-4.4M | ||
| Q1 24 | $2.3M | $-4.1M |
| Q4 25 | — | 61.5% | ||
| Q3 25 | — | 63.2% | ||
| Q2 25 | — | 60.3% | ||
| Q1 25 | — | 60.5% | ||
| Q4 24 | — | 61.3% | ||
| Q3 24 | — | 59.7% | ||
| Q2 24 | — | 63.5% | ||
| Q1 24 | — | 59.2% |
| Q4 25 | 44.3% | -67.7% | ||
| Q3 25 | 34.5% | -59.5% | ||
| Q2 25 | 35.0% | -61.6% | ||
| Q1 25 | 27.4% | -72.6% | ||
| Q4 24 | 29.4% | -72.5% | ||
| Q3 24 | 19.4% | -63.5% | ||
| Q2 24 | 19.0% | -60.1% | ||
| Q1 24 | 20.8% | -55.2% |
| Q4 25 | 34.9% | — | ||
| Q3 25 | 27.5% | -66.5% | ||
| Q2 25 | 28.0% | -63.3% | ||
| Q1 25 | 22.3% | -71.0% | ||
| Q4 24 | 23.8% | — | ||
| Q3 24 | 16.4% | -61.2% | ||
| Q2 24 | 16.2% | -56.1% | ||
| Q1 24 | 17.6% | -54.3% |
| Q4 25 | — | $-0.26 | ||
| Q3 25 | — | $-0.21 | ||
| Q2 25 | — | $-0.21 | ||
| Q1 25 | — | $-0.22 | ||
| Q4 24 | — | $-0.20 | ||
| Q3 24 | — | $-0.18 | ||
| Q2 24 | — | $-0.16 | ||
| Q1 24 | — | $-0.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $126.8M | $45.9M |
| Total DebtLower is stronger | $18.4M | $49.1M |
| Stockholders' EquityBook value | $207.9M | $28.0M |
| Total Assets | $2.1B | $97.7M |
| Debt / EquityLower = less leverage | 0.09× | 1.75× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $126.8M | $45.9M | ||
| Q3 25 | $108.2M | $38.2M | ||
| Q2 25 | $95.2M | $41.5M | ||
| Q1 25 | $163.4M | $12.4M | ||
| Q4 24 | $101.2M | $20.1M | ||
| Q3 24 | $59.0M | $21.6M | ||
| Q2 24 | $63.4M | $32.8M | ||
| Q1 24 | $111.4M | $35.4M |
| Q4 25 | $18.4M | $49.1M | ||
| Q3 25 | — | $29.2M | ||
| Q2 25 | — | $28.8M | ||
| Q1 25 | — | — | ||
| Q4 24 | $20.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $10.0M | ||
| Q1 24 | — | $10.0M |
| Q4 25 | $207.9M | $28.0M | ||
| Q3 25 | $200.6M | $15.9M | ||
| Q2 25 | $193.0M | $19.7M | ||
| Q1 25 | $183.1M | $20.0M | ||
| Q4 24 | $174.7M | $25.4M | ||
| Q3 24 | $183.4M | $29.0M | ||
| Q2 24 | $167.1M | $32.1M | ||
| Q1 24 | $165.5M | $34.6M |
| Q4 25 | $2.1B | $97.7M | ||
| Q3 25 | $2.1B | $60.4M | ||
| Q2 25 | $2.1B | $62.9M | ||
| Q1 25 | $2.2B | $30.1M | ||
| Q4 24 | $2.1B | $39.2M | ||
| Q3 24 | $2.1B | $40.2M | ||
| Q2 24 | $2.1B | $52.6M | ||
| Q1 24 | $2.2B | $53.6M |
| Q4 25 | 0.09× | 1.75× | ||
| Q3 25 | — | 1.84× | ||
| Q2 25 | — | 1.46× | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.11× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.31× | ||
| Q1 24 | — | 0.29× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $21.3M | $-12.1M |
| Free Cash FlowOCF − Capex | $20.7M | $-12.1M |
| FCF MarginFCF / Revenue | 110.8% | -116.5% |
| Capex IntensityCapex / Revenue | 3.4% | 0.5% |
| Cash ConversionOCF / Net Profit | 3.28× | — |
| TTM Free Cash FlowTrailing 4 quarters | $34.2M | $-24.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $21.3M | $-12.1M | ||
| Q3 25 | $2.8M | $-3.1M | ||
| Q2 25 | $4.0M | $-2.6M | ||
| Q1 25 | $7.1M | $-6.2M | ||
| Q4 24 | $14.3M | $-1.2M | ||
| Q3 24 | $3.1M | $-1.2M | ||
| Q2 24 | $3.9M | $-2.7M | ||
| Q1 24 | $1.4M | $-3.8M |
| Q4 25 | $20.7M | $-12.1M | ||
| Q3 25 | $2.6M | $-3.3M | ||
| Q2 25 | $3.9M | $-2.6M | ||
| Q1 25 | $6.9M | $-6.4M | ||
| Q4 24 | $14.0M | $-1.5M | ||
| Q3 24 | $3.0M | $-1.2M | ||
| Q2 24 | $3.8M | — | ||
| Q1 24 | $1.3M | — |
| Q4 25 | 110.8% | -116.5% | ||
| Q3 25 | 16.0% | -37.5% | ||
| Q2 25 | 24.2% | -28.7% | ||
| Q1 25 | 44.8% | -74.9% | ||
| Q4 24 | 94.9% | -19.4% | ||
| Q3 24 | 22.5% | -14.9% | ||
| Q2 24 | 28.1% | — | ||
| Q1 24 | 10.0% | — |
| Q4 25 | 3.4% | 0.5% | ||
| Q3 25 | 0.6% | 2.2% | ||
| Q2 25 | 0.7% | 1.0% | ||
| Q1 25 | 1.3% | 2.2% | ||
| Q4 24 | 2.0% | 3.4% | ||
| Q3 24 | 0.5% | 0.1% | ||
| Q2 24 | 0.7% | 0.0% | ||
| Q1 24 | 0.5% | 0.0% |
| Q4 25 | 3.28× | — | ||
| Q3 25 | 0.60× | — | ||
| Q2 25 | 0.89× | — | ||
| Q1 25 | 2.07× | — | ||
| Q4 24 | 4.07× | — | ||
| Q3 24 | 1.40× | — | ||
| Q2 24 | 1.78× | — | ||
| Q1 24 | 0.59× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ATLO
Segment breakdown not available.
CLPT
| Neurosurgery Navigation And Therapy Disposable Products | $4.7M | 45% |
| Biologics And Drug Delivery Services And License Fees | $2.8M | 27% |
| Biologics And Drug Delivery Disposable Products | $2.4M | 23% |
| Other | $502.0K | 5% |
